Form 8-K - Current report:
SEC Accession No. 0001564590-21-034107
Filing Date
2021-06-24
Accepted
2021-06-24 06:03:23
Documents
14
Period of Report
2021-06-19
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-8k_20210619.htm   iXBRL 8-K 141943
2 EX-10.1 eypt-ex101_16.htm EX-10.1 488505
3 EX-10.2 eypt-ex102_17.htm EX-10.2 355205
  Complete submission text file 0001564590-21-034107.txt   1205881

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eypt-20210619.xsd EX-101.SCH 5784
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20210619_lab.xml EX-101.LAB 18719
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20210619_pre.xml EX-101.PRE 11181
7 EXTRACTED XBRL INSTANCE DOCUMENT eypt-8k_20210619_htm.xml XML 3421
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 211040519
SIC: 3826 Laboratory Analytical Instruments